drugset / Trial / NCT00771381

A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer

NCT00771381

Phase 2 Terminated 23 enrolled AHS Cancer Control Alberta
NaSingle-groupOpen-labelDiagnostic

Summary

In about half the cases of breast cancer, there is hypoxic (no, or little oxygen) tissue present. Hypoxic cells can be resistant to treatment and may cause increased tumour growth. This study will use 18F-FAZA PET scans before surgery or treatment to assess whether patients have hypoxic tumours. The results will be compared to tissue samples removed during surgery and to the distribution of 18F-FDG.

Timeline

Start
2008-11-28
Primary completion
2019-02-04
Completion
2019-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FAZA Diagnostic / imaging agent 110 mbq
Subject 18F-FAZA Diagnostic / imaging agent 600 mbq
Subject 18F-FDB Diagnostic / imaging agent 100 mbq
Subject 18F-FDB Diagnostic / imaging agent 700 mbq

Indications